{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:29:56Z","timestamp":1793690996296,"version":"4.5.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,30]]},"DOI":"10.7759\/cureus.61374","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T13:17:55Z","timestamp":1717075075000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Novel Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Priyansh","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni H","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshaya","family":"Siddegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvana Rasagna","family":"Potini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Miriyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00520-9","article-title":"Electroimmunology and cardiac arrhythmia","volume":"18","author":"Grune J","year":"2021","unstructured":"Grune J, Yamazoe M, Nahrendorf M. Electroimmunology and cardiac arrhythmia. Nat Rev Cardiol. 2021, 18:547-64. 10.1038\/s41569-021-00520-9","journal-title":"Nat Rev Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-11-0191","article-title":"Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial","volume":"75","author":"Hori M","year":"2011","unstructured":"Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. Circ J. 2011, 75:800-5. 10.1253\/circj.cj-11-0191","journal-title":"Circ J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208824","article-title":"Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants","volume":"13","author":"Morgan A","year":"2018","unstructured":"Morgan A, Joshy G, Schaffer A, Laba TL, Litchfield M, Pearson S, Banks E. Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants. PLoS One. 2018, 13:e0208824. 10.1371\/journal.pone.0208824","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina R","year":"2012","unstructured":"De Caterina R, Husted S, Wallentin L, et al.. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012, 59:1413-25. 10.1016\/j.jacc.2012.02.008","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref6","unstructured":"An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation. (2014). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00403767."},{"key":"ref7","unstructured":"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE). (2018). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00412984."},{"key":"ref8","unstructured":"Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation. (2015). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00494871."},{"key":"ref9","unstructured":"A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation. (2019). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00504556."},{"key":"ref10","unstructured":"Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48). (2019). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00781391."},{"key":"ref11","unstructured":"A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation. (2013). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00787150."},{"key":"ref12","unstructured":"DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation. (2019). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00806624."},{"key":"ref13","unstructured":"Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation. (2019). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00829933."},{"key":"ref14","unstructured":"A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin. (2014). Accessed. May 10, 2024: https:\/\/www.clinicaltrials.gov\/study\/NCT01136408."},{"key":"ref15","unstructured":"Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation (TripleAXEL). (2017). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT02042534."},{"key":"ref16","unstructured":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) (ENSURE-AF). (2019). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT02072434."},{"key":"ref17","unstructured":"Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque. (2019). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT02090075."},{"key":"ref18","unstructured":"Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation (AREST). (2021). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT02283294."},{"key":"ref19","unstructured":"Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare. (2023). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT04681482."},{"key":"ref20","unstructured":"Sequential Expansion of Comparative Effectiveness of Anticoagulants. (2019). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT02081807."},{"key":"ref21","unstructured":"Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment. (2023). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT04435769."},{"key":"ref22","unstructured":"Comparative Effectiveness and Safety Between Warfarin and Dabigatran. (2019). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT03254134."},{"key":"ref23","unstructured":"The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage. (2017). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT02061748."},{"key":"ref24","unstructured":"The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage. (2015). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT02043808."},{"key":"ref25","unstructured":"Comparative Effectiveness of Oral Anticoagulants. (2014). Accessed. May 10, 2024: https:\/\/clinicaltrials.gov\/study\/NCT01847547."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309901","article-title":"Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation","volume":"103","author":"Bahit MC","year":"2017","unstructured":"Bahit MC, Lopes RD, Wojdyla DM, et al.. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017, 103:623-8. 10.1136\/heartjnl-2016-309901","journal-title":"Heart"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Jaspers Focks J","year":"2016","unstructured":"Jaspers Focks J, Brouwer MA, Wojdyla DM, et al.. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial. BMJ. 2016, 353:i2868. 10.1136\/bmj.i2868","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen S","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, et al.. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial. Eur Heart J. 2014, 35:1864-72. 10.1093\/eurheartj\/ehu046","journal-title":"Eur Heart J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy141","article-title":"Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: An analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study","volume":"20","author":"Goette A","year":"2018","unstructured":"Goette A, Kwong WJ, Ezekowitz MD, Banach M, Hjortshoj SP, Zamoryakhin D, Lip GY. Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: An analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study. Europace. 2018, 20:1936-43. 10.1093\/europace\/euy141","journal-title":"Europace"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: Insights from the ENGAGE AF-TIMI 48 trial","volume":"129","author":"Giugliano RP","year":"2016","unstructured":"Giugliano RP, Ruff CT, Wiviott SD, et al.. Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: Insights from the ENGAGE AF-TIMI 48 trial. Am J Med. 2016, 129:850-857.e2. 10.1016\/j.amjmed.2016.02.028","journal-title":"Am J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.05.028","article-title":"Transition of patients from blinded study drug to open-label anticoagulation: The ENGAGE AF-TIMI 48 trial","volume":"64","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.. Transition of patients from blinded study drug to open-label anticoagulation: The ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014, 64:576-84. 10.1016\/j.jacc.2014.05.028","journal-title":"J Am Coll Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-13-1324","article-title":"Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age","volume":"78","author":"Hori M","year":"2014","unstructured":"Hori M, Matsumoto M, Tanahashi N, et al.. Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circ J. 2014, 78:1349-56. 10.1253\/circj.cj-13-1324","journal-title":"Circ J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht428","article-title":"Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: Results from the ROCKET AF trial","volume":"35","author":"Mahaffey KW","year":"2014","unstructured":"Mahaffey KW, Stevens SR, White HD, et al.. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: Results from the ROCKET AF trial. Eur Heart J. 2014, 35:233-41. 10.1093\/eurheartj\/eht428","journal-title":"Eur Heart J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft111","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: A subgroup analysis of the RE-LY trial","volume":"15","author":"Ferreira J","year":"2013","unstructured":"Ferreira J, Ezekowitz MD, Connolly SJ, et al.. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: A subgroup analysis of the RE-LY trial. Eur J Heart Fail. 2013, 15:1053-61. 10.1093\/eurjhf\/hft111","journal-title":"Eur J Heart Fail"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eux022","article-title":"Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation\u2014the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study","volume":"20","author":"Verdecchia P","year":"2018","unstructured":"Verdecchia P, Reboldi G, Angeli F, et al.. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation\u2014the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2018, 20:253-62. 10.1093\/europace\/eux022","journal-title":"Europace"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.042","article-title":"Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation","volume":"62","author":"Eikelboom JW","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Hart RG, et al.. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013, 62:900-8. 10.1016\/j.jacc.2013.05.042","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/246772-effectiveness-of-novel-oral-anticoagulants-versus-warfarin-in-patients-with-atrial-fibrillation-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:06:19Z","timestamp":1793689579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/246772-effectiveness-of-novel-oral-anticoagulants-versus-warfarin-in-patients-with-atrial-fibrillation-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.61374","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}